Navigation Links
Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment.
Date:8/14/2009

BELGRADE, SERBIA, Aug. 14 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced today that there is great progress being made with the experimental findings to aid in the suppression or ultimately the cure of Multiple Sclerosis not only in their lab in Belgrade, but around the world. (See unauthorized news link)

http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20090812/mtl_090812/20090812?hub=Health

In a recent study posted on Aug. 12, 2009 scientists have reversed the Multiple Sclerosis in mice. The study showed the suppression of the immune cells, forcing remission and reversing the disease in mice.

Multiple Sclerosis attacks the central nervous system. The researchers explained that "The new treatment, called GIFT15, is composed of two proteins, GSM-CSF and interleukin-15, that are fused in the lab. Normally, the individual proteins act to stimulate the immune system, but when they're stuck together, the proteins suppress immune response, the researchers explained. They do this by converting B-cells -- a type of white blood cell normally involved in immune response -- into immune suppressive cells."

Dr. Jacques Galipeau and his collegues of the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal, took normal B-cells from mice and sprinkled GIFT-15 on the B-cells and when this was given in a single dose intravenously back to the mice that were ill with Multiple sclerosis not only did the disease go away but no significant side effects were seen in the mice as per the researchers.

Researchers in Belgrade are also making progress via using other methodologies that involve Ribavirin and Tiazofurin. Administration of ribavirin and tiazofurin attenuated proliferation of autoreactive T lymphocytes and their infiltration into the nervous tissue, and thereby prevented myelin destruction. These results are encouraging for the future of MS therapy.

In other company news, The company has received many inquiries from its shareholders and followers visa vie meeting the August 15th Q2 financials filings deadline. Mr. Terry Yuan CEO of HTDS said, "The management has decided to release HTDS consolidated financials today August 14th 2009 shortly after the market closes. The reason for that is twofold.

One, we are very pleased where our share price now sits as of close of business day August 13 2009.We have come a long way from being a sub,sub, penny stock, to a transparent well organized, well capitalized company; together with having the market finally begin to recognize our values, and the work our team is doing in Serbia and here in China. HTDS management's aim is to continue with a good solid pace of adding value to HTDS and our shareholders. Secondly, HTDS management goal is to reward both our long and midterm shareholders, instead of catering to those seeking a daily quick profit. We remind our followers that the Q2 financial numbers, obviously will not reflect the recently announced contracts."

Additional details and information will be released as they become available, via regular news releases or via Pink Sheets filing service.

Safe Harbor Statement:

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MRI may be unnecessary prior to treatment in most newly diagnosed breast cancer patients
2. Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults
3. CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009
4. Treat Mind, Body in RA Patients: Study
5. Centers of Excellence Awards Presented to Over 100 Nursing Facilities as Nursing Facilities Reach the Tipping Point in Treating Pressure Ulcers
6. Interventional radiology treatment for uterine fibroids: Safe, nonsurgical option
7. Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option
8. TrueVision Teams with Ophthalmologists to Help Cure World Blindness for Treatable Cataracts -- Debut of 3D Training Video for Manual, Small-Incision Cataract Surgery
9. EVEREST Data Demonstrates Acute Reduction of Mitral Regurgitation Without Procedural Mortality in Patients Treated With the MitraClip(R) Therapy
10. OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma
11. Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa ... Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies ... few hospitals and facilities have earned this distinction. This is the second time ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa ... (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions of ... Hoessel to vice president of sales. , Litsinger joined Mirixa in 2008 ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims to ... that are both engaging and easy to use. Coming off the heels of ... revealed today its plans to roll out new AI-powered self-service enhancements to help ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into ... claim in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th ... According to the study, medical payments per claim in California decreased 4 percent in ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Hamilton County, is embarking on a charity drive ... specializes in finding new homes for orphaned or neglected senior dogs in the ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016  RxWiki Inc., a digital ... digital marketing strategies of thousands of pharmacies through its ... Austin Inno,s "50 on Fire" Award in ... "We,re pleased to accept the award as one of ... Chief Executive Officer at RxWiki. "Our platform gives independent ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... newly issued shares of common stock, $0.01 par value (the ... underwritten public offering.  The final terms of the Offering will ... pricing, and there can be no assurance as to whether ... expects to use the net proceeds it will receive from ...
(Date:12/8/2016)... , Dec. 8, 2016 Global Interventional ... on the global interventional radiology market analyzes the ... report comprises an elaborate executive summary, including a ... segments and sub-segments. The research is a ... formed the bulk of our research efforts along ...
Breaking Medicine Technology: